ATOS · Atossa Therapeutics, Inc. · Investor Relations
$2.45
+0.00 (+0.00%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern.”View the 10-Q filed Aug 7, 2026
Market Cap
$20.06M
Shares
9.98M
Volume · Oct 6
54.64K
Avg daily vol (3M)
74.18K
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-05-19 | Endoxifen's Role in Breast Cancer | Virtual KOL Event | Event |
| 2025-10-22 | The Maxim Growth Summit | Event |
| 2025-09-08 | H.C. Wainwright 27th Annual Global Investment Conference | Conference |